4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BioCryst Pharmaceuticals, Inc. (BCRX) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Durham, United States with about 435 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, BCRX reported $875M in revenue and $264M in net income.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Interactive charts & full statements → Open the BCRX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $875M | $451M | $331M | $271M | — |
| Gross Profit | $856M | $438M | $327M | $264M | — |
| Operating Income (EBIT) | $341M | ($2M) | ($104M) | ($148M) | — |
| Net Income | $264M | ($89M) | ($226M) | ($247M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $156M | $407M | $159M | $163M | $146M | — |
| Gross Profit | $151M | $397M | $157M | $161M | $141M | — |
| Operating Income (EBIT) | ($702M) | $260M | $30M | $30M | $21M | — |
| Net Income | ($722M) | $246M | $13M | $5M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $514M | $490M | $517M | $550M | — |
| Total Liabilities | $633M | $966M | $972M | $845M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BCRX viewer.
About TickerBase · Data methodology & sources